SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors anticipate upcoming earnings and potential hyperscaler announcements, crucial for the company's AI infrastructure growth. Community discussions revolve around the timing of a new lease and the impact of Macquarie's recent funding draw. Bullish sentiment remains high due to the expected increase in AI data center demand and APLD's strategic position.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending due to a strategic partnership to develop 'Made in US' post-quantum cryptography solutions for US government and defense, sparking bullish sentiment. The community is actively discussing the potential for a short squeeze and significant upside, drawing comparisons to other quantum stocks. With high trading volume and positive news, investors are optimistic about the company's future growth and potential double-digit price targets.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending due to recent AI partnerships, sparking investor excitement about its potential in the agentic AI space; some view it as undervalued compared to competitors like $PLTR. The community is discussing its strategic shift from RPA to AI-driven automation and whether it can sustain growth, while others are eyeing potential short squeezes.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as gold prices surge to new all-time highs, driven by safe-haven demand amid economic uncertainty and geopolitical tensions, potentially signaling a broader market correction. Community members are actively debating whether this rally is sustainable, with some pointing to overbought conditions while others anticipate further gains due to ongoing global instability and central bank activity. Discussions also revolve around the relationship between gold, the dollar, and other asset classes like equities and crypto.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge, nearing multi-decade highs, fueled by potential for a short squeeze and discussions of a 45-year cup and handle formation. Community chatter revolves around big banks potentially manipulating the price and excitement about silver's potential to reach new all-time highs. Some investors are adding to their positions, while others are taking profits or expressing concerns about a possible pullback.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending amid discussions about defense spending, potential contract wins, and comparisons to other high-growth tech and defense companies. The community is actively debating its valuation, potential for acquisitions, and upcoming catalysts like government contracts and drone technology advancements. Some traders are taking profits after a significant run-up, while others see it as a long-term growth play.

Global Health Solutions Inc is an American company that works with partners to eliminate diseases that have plagued humanity for centuries and protect the health of populations by helping countries build strong health systems. The private company is located in the US. The company brings together key stakeholders around the world with a common goal to stop diseases and strengthen health systems through powerful partnerships. The company consists of programs and focus areas that cover a range of health issues including neglected tropical diseases, infectious diseases, vaccines, field epidemiology, public health informatics, health workforce development, and health ethics. The company's end goal is to eliminate diseases and protect the health of populations.

Turn Therapeutics Inc.

Turn Therapeutics Inc

Turn Therapeutics ($TTRX) is trending due to significant price volatility following its recent IPO, with the community actively debating potential short squeezes and bag holding scenarios. Discussions revolve around the stock's rapid price fluctuations and whether it represents a genuine opportunity or a classic pump-and-dump scheme. The stock's performance is also drawing comparisons to other recent high-flying biotech stocks.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending due to its expanding partnerships in the autonomous delivery space, particularly with DoorDash, sparking discussions about the company's growth potential and market dominance. Community members are actively discussing the high call option volume, potential for a short squeeze, and the long-term prospects of robotic food delivery. Despite some concerns about high operating costs, the stock is seeing increased attention as a strong relative strength name in the robotics sector.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy ($ENPH) is trending as the stock shows signs of bouncing back, prompting discussions about a potential breakout and short squeeze. Community members are actively debating whether the stock has hit its rock bottom and if it's poised for a significant upward move, while also noting positive momentum in the broader solar sector. Some analysts point to potential benefits from future interest rate cuts, even amidst concerns about policy headwinds.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid discussions around its valuation, potential for a short squeeze, and a recent healthcare partnership with OneMedNet; the community is debating whether the stock is overvalued and if it can sustain its high growth, while some point to the potential for breakout traders to drive the price higher. Bullish sentiment remains strong despite some concerns about the company's valuation and the sustainability of its growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hims & Hers Expands Personalized Care Access Via Telehealth Platform

HIMS expands its AI-powered telehealth platform, boosting personalized care and eyeing international growth in 2026.

GoodRx Announces Date for Third Quarter 2025 Earnings Release and Conference Call

GoodRx Holdings, Inc. (Nasdaq: GDRX) (GoodRx or the Company), the leading platform for medication savings in the U.S., today announced it will release its third quarter 2025 financial results after...

Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%

AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.

Amgen (AMGN) announced on Monday that eligible patients can access its drug Repatha at about a 60% discount from the current list price via its direct-to-patient program in the U.S.The program, called AmgenNow, follows the Trump Administration’s push to lower drug prices in the U.S. Repatha will be available through the platform at a monthly cost of $239, Amgen <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/amgen-makes-repatha-available-through-amgennow-a-direct-to-patient-program-in-the-us-302575486.html">said</a>. The company noted that the program is open to all patients, including those who are uninsured or in high-deductible health plans or prefer to pay with cash or out of pocket.The company also noted that the new direct-to-patient price is the lowest among the economically developed countries and is being offered solely to U.S. patients.Amgen’s Repatha is indicated for lowering low-density lipoprotein cholesterol, commonly referred to as “bad” cholesterol.Shares of the company traded over 1% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AMGN">AMGN stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.Amgen announced on Monday that it intends to make its direct-to-consumer platform accessible via the TrumpRx website, which was announced by the President last week and is slated for launch next year. The site will enable American consumers to purchase prescription drugs from pharmaceutical companies at a discount.In the second quarter of 2025, Repatha sales increased 31% year-over-year to $696 million, driven by 36% volume growth. This represented nearly 7.6% of the company’s overall revenue in the period.The announcement comes on the heels of President Trump sending letters to 17 drugmakers, including Amgen, in July, demanding that they lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations. Amgen announced on Monday that it would add other drugs to its AmgenNow platform.Separately, the medication savings platform GoodRx (GDRX) also said on Monday that patients can use the platform to access Repatha for $239 at more than 70,000 pharmacies U.S.-wide.AMGN stock is up by 14% this year but down by about 7% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-listed-nyxoah-shares-soar-on-first-genio-system-implants-in-patients-with-sleep-disorder/ch6R4LYR3g1">US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The company logo and the lettering of the biotechnology company Amgen can be seen on the facade of the company's headquarters in Munich (Bavaria) on January 14, 2025. Photo: Matthias Balk/dpa (Photo by Matthias Balk/picture alliance via Getty Images)

Amgen To Sell Cholesterol Drug For Approximately 60% Discount 

Patients can purchase Repatha at a discount through Amgen’s direct-to-patient program, AmgenNow. 

Equity

Patients can purchase Repatha at a discount through Amgen’s direct-to-patient program, AmgenNow. 


Hims & Hers Expands AI and Technology Focus to Advance Digital Care

HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.

U.S. equities edged lower in Monday’s midday trade as investors turned cautious ahead of Federal Reserve Chair Jerome Powell’s speech at the Jackson Hole symposium on Friday.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.08% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, fell 0.19%.Here are the top stocks making the biggest moves in Monday’s midday trade:<a href="https://stocktwits.com/symbol/DAY">Dayforce Inc. (DAY)</a>Dayforce shares skyrocketed 26% in Monday’s midday trade after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/thoma-bravo-eyes-takeover-of-hr-software-firm-dayforce-report/chsaxunRdQJ">reports</a> suggested that private equity firm Thoma Bravo is in talks to acquire the human resources firm.<a href="https://stocktwits.com/symbol/DAY">DAY stock</a> is down 8% year-to-date.<a href="https://stocktwits.com/symbol/APLD">Applied Digital Corp. (APLD)</a>Applied Digital shares gained over 14% in Monday’s midday trade after it&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/this-data-center-stock-doubled-in-2025/chsOWqERdX9">announced</a> plans to begin construction of its next-generation $3 billion AI campus, Polaris Forge 2, in September.<a href="https://stocktwits.com/symbol/APLD">APLD stock</a> is up 111% year-to-date.<a href="https://stocktwits.com/symbol/GDRX">GoodRx Holdings Inc. (GDRX)</a>GoodRx shares surged over 35% in Monday’s midday trade after Novo Nordisk&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-cuts-ozempic-cost-to-499-dollars-per-month-for-self-paying-patients/chsOfKDRdXE">announced</a> a collaboration with the drug savings platform to provide self-paying eligible type 2 diabetes patients with access to Ozempic at $499.<a href="https://stocktwits.com/symbol/GDRX">GDRX stock</a> is up 8% year-to-date.<a href="https://stocktwits.com/symbol/FSLR">First Solar Inc. (FSLR)</a>First Solar shares surged nearly 9% in Monday’s midday trade as investors cheered the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/solar-incentives-treasury-clears-the-air-fslr-run-enph-nee-stocks-in-focus/chsOJX1RdQy">clarity offered</a> by the U.S. Treasury Department and the Internal Revenue Service regarding wind and solar incentives. Shares of other clean energy companies, like SolarEdge Technologies Inc. (SEDG), Sunrun Inc. (RUN), Enphase Energy Inc. (ENPH), and NextEra Energy Inc. (NEE), also rose.<a href="https://stocktwits.com/symbol/FSLR">FSLR stock</a> is up 23% year-to-date.<a href="https://stocktwits.com/symbol/WULF">TeraWulf Inc. (WULF)</a>TeraWulf shares surged more than 11% in Monday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/terawulf-launches-400-million-convertible-note-offering/chsO7yLRdQx">announced</a> plans to raise $400 million through a private offering of convertible senior notes due in 2031. Alphabet Inc.’s (GOOG/GOOGL) Google also extended its backstop to $3.2 billion from $1.8 billion, with its stake in the company increasing to nearly 14%.<a href="https://stocktwits.com/symbol/WULF">WULF stock</a> is up 76% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-warns-investors-be-prepared-goldilocks-dominating-equity-markets/chsOiYdRdXg">JPMorgan Warns Investors To Brace For Incoming Volatility, Says ‘Goldilocks’ Narrative Still Dominating Markets: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Dayforce, Applied Digital, GoodRx, First Solar, TeraWulf: Stocks Making The Biggest Moves Today

Dayforce shares skyrocketed 26% in Monday’s midday trade after reports suggested that private equity firm Thoma Bravo is in talks to acquire the human resources firm.

Danish drugmaker Novo Nordisk (NVO) has announced that it will allow self-paying eligible type 2 diabetes patients access to its Ozempic for $499 per month starting Monday via multiple platforms, including drug savings platform GoodRx (GDRX).The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face prices at or above wholesale cost. The offer will also be available through the company’s online pharmacy, NovoCare, as well as the drug’s official website.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-slashes-full-year-guidance/cho9UwAR5yE">NVO</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels. Shares of the company traded 5% higher on Monday morning at the time of writing.The offer comes as the company battles the compounding of its blockbuster medicines. Last month, Novo lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and Ozempic for the second half of the year. While the U.S. Food and Drug Administration has prohibited mass compounding for the active component in Wegovy and Ozempic called Semaglutide, unsafe and unlawful mass compounding has continued, the company said, citing its market research.“We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that's one too many. This is why we felt it was important to make Ozempic, the GLP-1 with the broadest range of FDA-approved indications for adults with type 2 diabetes, more affordable to those without insurance who deserve the real thing," <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916418">said</a> Dave Moore, Executive Vice President, U.S. Operations of Novo Nordisk Inc.As part of Novo’s collaboration with GoodRx, self-paying patients can get all strengths of both Wegovy and Ozempic for $499 per month through the GoodRx platform. Eligible patients can use GoodRx to self-pay for Ozempic and Wegovy pens for $499 per month at over 70,000 retail pharmacies nationwide, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.goodrx.com/news-releases/news-release-details/goodrx-announces-collaboration-novo-nordisk-expand-access">said</a>. Shares of <a href="https://stocktwits.com/symbol/GDRX">GDRX </a>traded 31% higher following the news.While NVO stock is down by 37% this year, GDRX is up by 5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/lakeshore-biopharma-got-an-acquisition-proposal-from-oceanpine-capital/chsO9ANRdXT">LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Stock Surges After Pharma Major Cuts Ozempic Cost to $499 Per Month For Self-Paying Patients

The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face prices at or above wholesale cost.

Compared to Estimates, GoodRx (GDRX) Q2 Earnings: A Look at Key Metrics

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

GoodRx Holdings, Inc. (GDRX) Q2 Earnings and Revenues Lag Estimates

GoodRx (GDRX) delivered earnings and revenue surprises of -10.00% and -1.03%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Surgery Partners (SGRY) Q2 Earnings and Revenues Beat Estimates

Surgery Partners (SGRY) delivered earnings and revenue surprises of +6.25% and +0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

GoodRx Holdings Inc - Ordinary Shares - Class A

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

GDRX
GoodRx Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GDRX News

GDRX GoodRx Holdings Inc